Published Date: 12/06/2024
Expiration Date: 10/21/2027
Throughout the history of the HIV/AIDS epidemic, the most critical advances in care and prevention have been made possible through the research and development of better and better antiretroviral treatments and strategies. As far as we have come, this basic tenet is still true as we continue the search for safer and even more effective agents. To bring us up to date, PRN is proud to welcome back Dr. Roy (Trip) Gulick for his perspective of the drug development pipeline and emerging treatment and prevention strategies.
Roy M. Gulick, MD, MPH research interests include designing, conducting and analyzing clinical trials to refine antiretroviral therapy strategies for HIV treatment and prevention and assess agents with new mechanisms of action. He currently serves as Principal Investigator of the Cornell-New Jersey HIV Clinical Trials Unit of the ACTG and the HIV Prevention Trials Network (HPTN), sponsored by the NIH.
